Charles River Laboratories International, Inc.
CRL
$291.76
$9.423.34%
NYSE
| 06/27/2026 | 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.72% | 1.18% | -0.83% | -0.49% | 0.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.72% | 1.18% | -0.83% | -0.49% | 0.59% |
| Cost of Revenue | -3.63% | 4.46% | -2.56% | 1.67% | -1.49% |
| Gross Profit | -1.18% | -5.02% | 2.87% | -4.25% | 4.30% |
| SG&A Expenses | 15.26% | -15.43% | -0.63% | -7.30% | 12.04% |
| Depreciation & Amortization | -49.04% | -48.44% | 123.21% | -15.43% | -10.73% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.90% | -1.52% | 3.50% | -0.92% | 0.83% |
| Operating Income | -11.79% | 18.33% | -47.39% | 2.05% | -0.62% |
| Income Before Tax | -25.55% | -183.22% | -35.66% | -4.43% | -40.31% |
| Income Tax Expenses | 188.01% | -249.90% | -485.05% | 51.07% | -26.26% |
| Earnings from Continuing Operations | -101.44% | -157.20% | -29.26% | -20.97% | -44.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -96.73% | 89.98% | 64.57% | -77.74% | -103.89% |
| Net Income | -102.83% | -158.28% | -28.93% | -21.87% | -44.38% |
| EBIT | -11.79% | 18.33% | -47.39% | 2.05% | -0.62% |
| EBITDA | -13.62% | 6.14% | 12.90% | -30.05% | -2.83% |
| EPS Basic | -102.90% | -160.33% | -33.22% | -17.25% | -39.01% |
| Normalized Basic EPS | 5.61% | -90.65% | -10.95% | -11.29% | 6.31% |
| EPS Diluted | -102.92% | -160.64% | -33.22% | -17.29% | -39.08% |
| Normalized Diluted EPS | 5.96% | -90.61% | -10.95% | -11.35% | 6.56% |
| Average Basic Shares Outstanding | -2.30% | -3.41% | -3.76% | -4.24% | -4.66% |
| Average Diluted Shares Outstanding | -2.63% | -3.74% | -3.76% | -4.18% | -4.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |